TC BioPharm

What TC BioPharm does

TC BioPharm (Holdings) PLC was a Scotland-incorporated, publicly traded clinical-stage cell therapy company developing allogeneic gamma-delta T cell therapies for cancer and infectious disease. Founded in 2013 and headquartered in Holytown, Motherwell, with manufacturing operations in Glasgow, the company pursued an integrated model covering preclinical development through clinical trials. Its lead product candidate, OmnImmune (TCB-008), was an allogeneic gamma-delta T cell therapy targeting relapsed/refractory acute myeloid leukemia (AML) and was being evaluated in the Phase 2B ACHIEVE clinical trial. A broader pipeline included TCB-002 for solid tumors and hematological malignancies, TCB-001, and adjunctive work on infectious disease applications including an announced H5N1 proof-of-concept study. The company differentiated through claimed safer, lower-cost off-the-shelf cell therapy relative to autologous CAR-T alternatives, supported by a European patent granted in April 2025 covering modified gamma-delta T cells for microbial, oncological, and viral indications.

The company had no approved products and generated no product revenue at any point. Capital formation relied on a sequence of small public offerings and private placements on Nasdaq (ticker TCBP), facilitated by H.C. Wainwright & Co., totaling roughly $25 million between 2022 and 2024 alongside warrant exercises and a £3.1 million private placement in May 2024. A non-dilutive $250,000 manufacturing optimization grant from ScaleReady's G-Rex program supplemented this funding in November 2024. The company posted net losses of £12.2 million in FY2024 and £5.9 million in FY2023, with an accumulated deficit of £51.0 million as of December 31, 2024, and cash of only £2.0 million as of May 7, 2025. The ADSs were delisted from Nasdaq on March 21, 2025 and moved to OTC Pink under TCBPY.

Financial deterioration culminated in the appointment of joint administrators on October 2, 2025 and full liquidation, with all staff made redundant. The company's allogeneic gamma-delta T cell technology (TCB-002) was acquired by Singapore-based CytoMed Therapeutics in November 2025, which intends to deploy the platform in China and India. A previously announced non-binding LOI to acquire a commercial-stage ophthalmic pharmaceutical company for near-term revenue was never completed.

Name

TC BioPharm

Legal name

TC BioPharm (Holdings) PLC

Website

https://tcbiopharm.com

Company type

Public

Founded year

2013

Operating status

Acquired

Headcount range

51–100 employees

Short description

TC BioPharm was a Scotland-based, publicly traded clinical-stage biotech developing allogeneic gamma-delta T cell therapies for cancer (notably AML) and infectious disease; pre-revenue with no approved products, it entered administration in October 2025 and its core technology was acquired by CytoMed Therapeutics.

Ownership category

akta.pro rank

Product category

Cell Therapy / Oncology Biologics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

CAR-T & TCR-T Therapies (HLAAABAC)

Keywords

• Cell therapy
• Gamma-delta T cells
• Allogeneic immunotherapy
• CAR-T oncology
• Cell-based biologics

Headquarters

HQ city

Holytown

HQ country

United Kingdom

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Marketing or Sales

Revenue model

1. Product Revenue: Pre-revenue clinical-stage company. No products approved for commercial sale. Expected to generate product revenues only after obtaining regulatory approval for commercial sale of GD-T cell-based therapeutic candidates.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

TC BioPharm is a clinical-stage cell therapy company developing allogeneic gamma-delta T cell therapies for the treatment of hematological malignancies (lead indication: relapsed/refractory Acute Myeloid Leukemia) and solid tumors. Its lead product candidate, OmnImmune (TCB-008), is an off-the-shelf allogeneic CAR-T cell therapy evaluated in the Phase 1b/2a ACHIEVE clinical trial. The company also develops gamma-delta T cell candidates for infectious disease indications and operates cGMP cell therapy manufacturing facilities.

Product overview

TC BioPharm is a clinical-stage cell therapy company developing allogeneic gamma-delta T cell therapies for cancer treatment. Their product portfolio centers around OmnImmune® (TCB-008) as the lead product candidate for Acute Myeloid Leukemia, alongside CAR-T cell therapy products built on their gamma-delta T cell platform. The company operates their integrated model driving products from preclinical testing through clinical development. Their pipeline includes multiple clinical trials including the ACHIEVE trial (Phase 1b/2a) and TCB-001. The company has also developed allogeneic gamma delta T cell technology (TCB-002) which was divested to CytoMed Therapeutics. TC BioPharm focuses on developing safer, less expensive CAR-T products that can target more cancers using their gamma-delta T cell platform, while also developing therapies for infectious diseases.

Differentiator

Problem solved

Functional benefit

Brands

• OmnImmune: Lead product candidate - allogeneic gamma-delta T cell therapy for cancer treatment.

Quantifiable outcome

• Phase 2B ACHIEVE clinical trial ongoing for AML treatment
• +3 more outcomes

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature4 records

Partnerships

Two partnerships are on record, tiered core and minor.

• CytoMed Therapeutics LimitedcoreStrategic or Co-development Partner · 18 November 2025CytoMed Therapeutics acquired TC BioPharm's allogeneic gamma delta T cell technology (TCB-002) to develop cell-based immunotherapies for cancer. CytoMed plans to collaborate with partners in China and India to adapt the technology leveraging recent Chinese regulations on cell therapies. TC BioPharm had collapsed into liquidation earlier in 2025.
• ScaleReadyminorStrategic or Co-development Partner · 12 November 2024TC BioPharm received a non-dilutive $250,000 grant from ScaleReady's G-Rex Grant Program. The grant supports manufacturing process optimizations for the TCB008 product, aiming to enhance yield and reduce production costs while accelerating development efforts for the Phase 2B clinical trial for acute myeloid leukemia.

Scale indicators12 records

Recent moves7 records

Expansion highlights4 records

Direct peers

• Adaptimmune Therapeutics: Clinical-stage biotech developing engineered T cell therapies including SPEAR T-cells for solid tumors. Comparable as a developer of cell-based immunotherapies for cancer targeting both hematological and solid tumor indications.
• Caribou Biosciences: Clinical-stage biotech developing allogeneic CAR-T cell therapies using CRISPR gene editing. Comparable as a developer of off-the-shelf allogeneic CAR-T therapies for hematologic malignancies and other cancers.
• Adicet Bio: Clinical-stage biotech developing allogeneic gamma-delta T cell therapies for hematological malignancies and solid tumors. Directly comparable in platform modality (gamma-delta T cells) and target patient population.
• Precision BioSciences: Clinical-stage biotech developing allogeneic CAR-T cell therapies using its ARCUS gene editing platform. Comparable as a developer of off-the-shelf engineered T cell therapies targeting cancer.
• Allogene Therapeutics: Clinical-stage biotech focused on allogeneic CAR-T cell therapies for cancer. Comparable as a developer of off-the-shelf engineered T cell therapies targeting hematologic malignancies using a similar allogeneic manufacturing model.
• CytoMed Therapeutics: Singapore-based biotech that acquired TC BioPharm's TCB-002 allogeneic gamma-delta T cell technology in 2025. Most directly comparable as a clinical-stage developer of gamma-delta T cell therapies for cancer, with similar target indications and platform architecture.

Broad incumbents

• Bristol-Myers Squibb: Major pharma with approved CAR-T products Breyanzi and Abecma. Comparable as a major incumbent in CAR-T therapy for hematologic malignancies, including AML-adjacent indications where TC BioPharm's OmnImmune was being developed.
• Cellectis: Clinical-stage biotech with proprietary allogeneic CAR-T platform (TALEN gene editing). Comparable as a broader allogeneic CAR-T platform developer with multiple programs across hematologic malignancies, though more mature and broader in scope than TC BioPharm.
• Gilead Sciences (Kite Pharma): Major pharma with leading CAR-T franchise Yescarta and Tecartus. Comparable as a developer of approved CAR-T therapies for hematologic malignancies, representing the commercial benchmark TC BioPharm would have competed against.
• CRISPR Therapeutics: Clinical- and commercial-stage gene editing company with approved CASGEVY (exa-cel) and a pipeline of allogeneic CAR-T programs. Comparable as a developer of gene-edited cell therapies, though broader and further advanced than TC BioPharm.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat2 records

Key risks6 records

Key highlights6 records

Customer concentration

• Xx.com/TCBioPharm
• Facebookfacebook.com/tcbiopharm
• LinkedInlinkedin.com/company/5094083

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds18 records

Investors11 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TC BioPharm